Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Structure Therapeutics Inc.
Headquarters: South San Francisco, CA, United States of America
Website: https://structuretx.com/
Year Founded: 2016
Status: Public
Industry Sector: HealthTechnology
CEO: Raymond C. Stevens, PhD
Number Of Employees: 163
Enterprise Value: $547,961,299
PE Ratio: -6.11
Exchange/Ticker 1: NASDAQ:GPCR
Exchange/Ticker 2: N/A
Latest Market Cap: $819,772,736
BioCentury | Dec 20, 2024
Product Development
Novo’s market cap slims down on CagriSema obesity data
Placebo-adjusted weight loss falls short of 25%+ expectations, doesn’t differentiate from Lilly’s Zepbound
BioCentury | Nov 15, 2024
Product Development
Pharmas challenging Novo and Lilly in obesity
An analysis of which major pharmas are in, out, or still deciding whether to take on obesity heavyweights Eli Lilly and Novo Nordisk
BioCentury | Oct 1, 2024
Management Tracks
Prothena names Swanson CDO
Plus: Chris Williams at the helm of Culture, GentiBio scoops up former Structure CMO and updates on Burning Rock, National Resilience and Grünenthal
BioCentury | Sep 20, 2024
Product Development
Novo’s Phase II miss in obesity oral amps up pressure on BD
Ph II data from CB1 blocker monlunabant show poor weight loss at 16 weeks, plus neuropsychiatric adverse events
BioCentury | Sep 18, 2024
Management Tracks
New CEOs at Nura, IMU
Plus: Structure strengthens team and updates from RegenxBio, Mirador, Abata, Entact, Nautilus and more
BioCentury | Sep 11, 2024
Product Development
Amycretin data highlight supply challenges for oral peptides in obesity
Although efficacy was strong, high dose likely makes oral amycretin commercially unviable
BioCentury | Jul 17, 2024
Product Development
Early data suggest best-in-class potential of Roche’s oral GLP-1 for obesity
Small molecule GLP-1 CT-996 shows over 6% weight loss at just 4 weeks
BioCentury | Jul 12, 2024
Finance
Still not over the hump, as biotech heads into 2H24
3Q24 Public Markets Preview: Conviction is the buzzword as investors weigh new opportunities
BioCentury | Jun 7, 2024
Finance
Public Equity Report: Rapport posts healthy first-day gain as Telix, Grail head for NASDAQ
Plus: Structure, Annexon and Summit follow clinical readouts by raising money
BioCentury | Jun 4, 2024
Product Development
Clinical Report: Obesity win for Structure, plus upbeat data for Annexon, Agios, Arrowhead, Ultragenyx, Intellia
Away from ASCO, handful of biotechs eye follow-ons or regularly submissions backed by new data
Items per page:
1 - 10 of 38